'It's Totally Irresponsible': Canadian Ethicist Slams Rogue Russian's Plan to Edit Human Embryos
By Gemma Buck,
National Post
| 07. 08. 2019
Canadian bioethicists and genetics experts are speaking out against Denis Rebrikov, the Russian molecular biologist who plans — in defiance of international scientific norms — to alter human embryos using CRISPR gene-editing technology to allow prospective parents with genetic deafness to conceive a child who can hear.
“We are putting ourselves on the path to changing the human evolutionary story. This is not up to one scientist. It’s not up to a group of scientists or a group of political elites. It’s up to all of us,” said Françoise Baylis, a professor of philosophy and bioethics at Dalhousie University who serves on a World Health Organization committee that is developing global standards and oversight for editing of the human genome.
The ethical implications of this kind of rogue science are wide-ranging and nuanced, Baylis explained. But the obvious ones are dire: Making genetic changes to eggs, sperm, or early embryos, collectively called the human germline, affects not only the eventual person these cells may become, but also their offspring.Though there is a “spectrum” of views among scientists and ethicists about...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...